Latest in News & Research
Efficacy, Safety of Tildrakizumab Maintained Through 52 Weeks for Scalp Psoriasis
Efficacy and safety for scalp psoriasis, seen at week 16, are maintained through week 52
Vitiligo-Like Depigmentation Seen With Use of Immunotherapy in Patients With Cancer
More localized VLD seen in study cohort; 140 of 200 patients had less than 10 percent of body surface area affected
Cutaneous Melanoma Risk Elevated for Survivors of Specific Cancers
Increased risk seen in association with nine primary cancers, with highest risk at one to five years after diagnosis of primary cancer
LAUNCH ALERT: FDA Approves VTAMA (Tapinarof) Cream for Atopic Dermatitis
CLICK HERE to watch Dr James Del Rosso give his expert clinical insights on VTAMA for atopic dermatitis
Tecovirimat No Aid for Time to Lesion Resolution With Mpox
Additionally, interim analysis shows that the antiviral is safe but has no effect on pain among adults with mild-to-moderate clade II mpox
In Case You Missed It: FDA Approves Bimzelx for Psoriatic Arthritis
CLICK HERE to watch Dr James Del Rosso’s dermatologic deep dive on Bimzelx (bimekizumab) for psoriatic arthritis
FDA Expands Approval of Vtama to Include Atopic Dermatitis
FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
The monoclonal antibody treatment is for patients ages 12 years and older
LAUNCH ALERT: FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
CLICK HERE to watch Dr James Del Rosso provide an in-depth overview of Nemluvio (nemolizumab) for atopic dermatitis
Self-Guided Cognitive Therapy Intervention Noninferior in Atopic Dermatitis
Self-guided cognitive behavioral therapy intervention noninferior to clinician-guided therapy
Cutaneous Malignant Neoplasm Risk Elevated After Blood or Marrow Transplant
Risk factors for subsequent neoplasm risk include age 50 years and older at BMT, male sex, post-BMT immunosuppression
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
- EFFICACY: In...
Thicker Melanoma Tumor Size Tied to Higher Risk of 20-Year Melanoma-Related Death
Findings for primary tumors of 0.8 to 1.0 mm versus those <0.8 mm
Low-Dose Oral Minoxidil Effective for Alopecia in Breast Cancer
All patients receiving surgery/radiotherapy alone or with chemotherapy had improvement or stability of alopecia with LDOM
Dupilumab Efficacious for Atopic Dermatitis in Young Children
Findings seen for children with and without comorbidities, such as asthma, allergic rhinitis, food allergies
Incidence Rates of Cancer Not Increased in Patients With Vitiligo
Significantly lower risks for melanoma, lung cancer, bladder cancer seen for patients with vitiligo
Indoor Tanning Not Linked to Tumor Mutational Burden in Melanoma
TMB significantly associated with older age at diagnosis, history of nonmelanoma skin cancer, head and neck tumors
Celiac Disease Linked to Higher Risk for Developing Alopecia Areata
Risk 25 percent higher when comparing matched individuals with and without celiac disease
Risk for Meniere Disease Higher in Patients With Atopic Dermatitis
Older age, female sex, and allergic comorbidities increase risk for developing Meniere disease
Durable Response Seen With Three Years of Deucravacitinib in Psoriasis
Safety profile consistent, clinical response durable among patients with moderate-to-severe plaque psoriasis
Tumor Upstaging Occurs in 9.4 Percent of Cases of Invasive Melanoma
Patients with upstaged tumors experience higher overall and melanoma-specific mortality than those with nonupstaged tumors
High Ultraprocessed Food Intake Linked to Active Psoriasis
Association persists after adjustment for age, BMI, alcohol intake, and comorbidities
Nemolizumab Beneficial for Signs, Symptoms of Prurigo Nodularis
Greater proportion of those receiving nemolizumab monotherapy versus placebo achieved itch response, IGA success
24 of 1238